Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nezastomig + REGN4336
- Development stage
- Unknown
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nezastomig + REGN4336 is an investigational combination immunotherapy being developed by Regeneron Pharmaceuticals for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The regimen consists of two bispecific antibodies: nezastomig (REGN5678), which targets PSMA and CD28 to provide costimulatory 'Signal 2' to T-cells, and REGN4336, which targets PSMA and CD3 to provide the primary activation 'Signal 1'. By simultaneously engaging both receptors on T-cells and targeting the prostate-specific membrane antigen (PSMA) on tumor cells, this combination is designed to enhance T-cell proliferation and cytotoxic activity against prostate cancer cells while potentially improving the safety profile compared to high-dose CD3-bispecific monotherapy.
- Other names
- nezastomig + REGN4336
02
Targets
CD3 (T-cell surface glycoprotein CD3)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on nezastomig + REGN4336.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nezastomig + REGN4336.